Why the study?
Does metoprolol succinate retard improve therapeutic efficacy and safety in patients with cardiovascular disease compared to short-acting beta-blockers?
Does metoprolol succinate retard improve therapeutic efficacy and safety in patients with cardiovascular disease compared to short-acting beta-blockers?
Metoprolol succinate retard offers high therapeutic efficacy and safety, with pharmacokinetic and pharmacodynamic advantages over short-acting beta-blockers for the management of chronic heart failure.
May support metoprolol succinate retard in chronic heart failure; leaves open randomized confirmation versus short-acting agents.
This article presents the data on the therapeutic efficacy ofbeta-adrenergic blocking agentsin ischemic heart disease, chronic heart failure (CHF), arterial hypertension. We analyzed the basic pharmacological mechanism of action of these drugs class. The comparison of pharmacodynamic and pharmacokinetic characteristics of metoprolol succinate retard with other beta-adrenoreceptor-blocking agents showed metoprolol succinate advantage over the short-term drugs for treatment of CHF. According to the results of randomised clinical trialswe determined high therapeutic efficacy and safety of metoprolol succinate retard.
No takes yet. Share an insight, caveat, or question.
Baryshnikov et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: